Compare HUIZ & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HUIZ | HOTH |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.4M | 17.7M |
| IPO Year | 2019 | 2018 |
| Metric | HUIZ | HOTH |
|---|---|---|
| Price | $1.72 | $0.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $2.30 | ★ $5.00 |
| AVG Volume (30 Days) | 99.2K | ★ 3.1M |
| Earning Date | 03-27-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.69 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.58 | N/A |
| Revenue Next Year | $6.64 | N/A |
| P/E Ratio | $7.81 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.19 | $0.49 |
| 52 Week High | $4.16 | $2.12 |
| Indicator | HUIZ | HOTH |
|---|---|---|
| Relative Strength Index (RSI) | 51.29 | 48.75 |
| Support Level | $1.60 | $0.50 |
| Resistance Level | $2.12 | $1.12 |
| Average True Range (ATR) | 0.18 | 0.09 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 87.39 | 59.99 |
Huize Holding Ltd is an independent online insurance product and service platform in China. The company distributes on its platform insurance products underwritten by the insurance companies that cooperate with the company, which the company refers to as its insurer partners, and helps them reach a large number of insurance clients. The company's platform offers a digitalized insurance purchase experience and services through various internet and mobile internet channels. The company generates revenues from the insurance brokerage fees paid by its insurer partners.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).